Minimal residual disease in breast cancer

Cancer and Metastasis Reviews

Volumn 18, Issue 1, 1999, Pages 101-108

  Kvalheim, Gunnar ^a,b   Naume, Bjørn ^a   Nesland, Jahn M ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bone marrow; Breast cancer patients; Minimal residual disease

Indexed keywords

MESSENGER RNA; MONOCLONAL ANTIBODY; TUMOR MARKER;

ARTICLE; BLOOD; BONE MARROW; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; GENE EXPRESSION; HUMAN; IMMUNOCYTOCHEMISTRY; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BONE MARROW NEOPLASMS; BREAST NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM, RESIDUAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0032849291     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006216504892     Document Type: Article

References (29)

1. Henderson IC, Canellos GP: Cancer of the breast. N Engl J Med 302: 17-30, 1980
2. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immunotherapy. Lancet 339: 1-15, 1992
3. McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82: 1006-1115, 1990
4. Mansi JL, Easton D, Berger U, Gazet J-C, Ford HT, Dearnaley et al.: Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years follow-up. Eur J Cancer 27: 1552-1555, 1991
5. Diel IJ, Kaufmann M, Costa SD, Holle R, Minckwitz GV, Solomayer EF, Kaul S, Bastert G: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. JNCO 88: 1652-1658, 1997
6. Pantel K, Felber E, Schlimok G: Detection and characterization of residual disease in breast cancer. J Hematother 3: 315-322, 1994
7. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP: Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9: 1749-1756, 1991
8. Harbeck N, Untech M, Pache L, Eiermann W: Turnout cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 69: 566-571, 1994
9. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, et al.: Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341: 85-86, 1993
10. Moss TJ, Ross AA: The risk of tumor cell contamination in peripheral blood stem cell collections. J. Hematotherapy 1: 225-232, 1992
11. Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D, Winther C, Akard L, Jansen J, Copelan E, Meagher R, Herzig RH, Klumpp TR, Kahn DG, Warner NE: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82: 2605-2610, 1993
12. Sharp JG, Mann SL, Murphy B, Weekes C: Culture methods for the detection of minimal tumor contamination of hematopoietic harvests: a review. J Hematother 4: 141-148, 1994
13. Funke I, Schraut W: Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remain to be substantiated. JCO 16: 557-566, 1998
14. Zippelius A, Kufer Å, Honold G, Kollermann MW, Oberneder R, Schlimok G, Rietmuller G, Pantel K: Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. JCO 15: 2701-2708, 1998
15. Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, Passlick B, Riethmuller G: Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 3: 165-173, 1994
16. Naume B, Borgen E, Beiske K, Herstad T-K, Ravnås G, Renolen A, Thrane-Steen K, Trachsel S, Funderud S, Kvalheim G: Detection of isolated breast cancer cells in peripheral blood or bone marrow by immunomagnetic techniques. J Hematother 6: 103-114, 1997
17. Borgen E, Beiske K, Trachsel S, Nesland J, Kvalheim G, Herstad T, Schlichting E, Qvist H, Naume B: Immunocytochemical detection of isolated epithelial cells in bone marrow. Unspecific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol 185: 427-434, 1998
18. Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Pesek KW, Barber M, Saporito L, Woo SD, Coral F, Spector N, Rabinowe SN, Grossbard ML, Ritz J, Nadler LM: Detection by polymerase chain reaction of residual cells with the bel-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 12: 3449-3457, 1993
19. Lin F, Van Rhee F, Goldman JM, Cross NCP: Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 87: 4473-4478, 1996
20. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS: Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Onc 12: 475-482, 1994
21. Fields KK, Elfenbein GJ, Trudeau WL, Perkins JB, Janssen WE, Moscinski LC: Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Onc 14: 1868-1876, 1996
22. Braun S, Muller M, Hepp F, Schlimok G, Riethmuller G, Pantel K: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. JNCI 14: 1099-1100, 1998
23. Naume B, Borgen E, Kvalheim G, Giercksky KE, Ovist H, Schlichting E, Kåresen R, Nesland JM: Detection of isolated tumor cells in bone marrow in localised breast cancer. Abstract. 2nd International symposium on minimal residual cancer, 1998
24. Kvalheim G, Erikstein B, Hervik I, Pharo A, Sommer H, Anker G, Telhaug R, Kolstad A, Nesland JM: Micrometastases in marrow and blood in high-risk stage II breast cancers before/after high-dose therapy. Blood 90; Suppl 1: 443a, 1998
25. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L: Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83: 636-640, 1994
26. Schlimok K, Pantel K, Loibuer H, Fackler-Schwalbe I, Riethmuller G: Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumours. Eur J Cancer 11: 1799-1803, 1995
27. Naume B, Borgen E, Nesland JM, Beiske K, Gilen E, Renolen A, Ravnås G, Qvist H, Kåresen R, Kvalheim G: Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Int J Cancer 78: 556-560, 1998
28. Pantel K, Felber E, Schlimok G: Detection and characterization of residual disease in breast cancer. J Hematother 3: 315-322, 1994
29. Disis ML, Cheever MA, HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Avd Cancer Res 71: 343-371, 1997